Barclays lowered the firm’s price target on Bluebird Bio (BLUE) to $8 from $40 and keeps an Overweight rating on the shares. The company reported a Q4 revenue beat with 2024 cell collections largely in line. Guidance for Bluebird’s cash runway is Q2 of 2025, with a key focus on closing of merger to avoid potential risks of bankruptcy and liquidation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- Bluebird Bio confirms receipt non-binding proposal from Ayrmid
- Biotech Alert: Searches spiking for these stocks today
- Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
- Bluebird Bio upgraded to Neutral from Underweight at JPMorgan
- BLUE Earnings Report this Week: Is It a Buy, Ahead of Earnings?